3C
ANIP icon

361 Capital’s ANI Pharmaceuticals ANIP Stock Holding History

361 Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,671
Closed -$1.65M – 326
2018
Q2 		$1.65M Buy
24,671
+812
+3% +$50.7K 0.37% 119
2018
Q1 		$1.39M Sell
23,859
-12,193
-34% -$774K 0.34% 174
2017
Q4 		$2.32M Buy
+36,052
New +$2.24M 0.58% 54

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

361 Capital's ANIP Position: Q3 2018 in Review

361 Capital sold out of ANI Pharmaceuticals (ANIP) in Q3 2018, closing a stake of 24,671 shares — an estimated $1.65M sold.

361 Capital first reported a position in ANIP in Q4 2017 and held it in 3 quarters. The position peaked at $2.32M in Q4 2017. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

  • 361 Capital reported no remaining ANI Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • 361 Capital sold 24,671 ANI Pharmaceuticals shares in Q3 2018, an estimated $1.65M.
  • 361 Capital first reported a position in ANI Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • 361 Capital's ANI Pharmaceuticals position peaked at $2.32M in Q4 2017.
  • 173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on 361 Capital's 13F filing for Q3 2018, filed 13 Nov 2018.